Amgen Inc.

Tularik Limited

Other

Sumitomo Pharmaceuticals Company Limited

Bei Shan

Julio Cesar Medina

Wenyan Shen

John A Flygare

Terry J Rosen

David Louis Clark

Simon Mark Jackson

Chadwick Terence King

Randal Robert Ketchem

Christopher Mehlin

Hui Tian

Teresa Arazas Carabeo

Derek Evan Piper

Jin-Long Chen

Nigel Pelham Clinton Walker

Mingyue Zhou

Joshua Schultz

Frank Kayser

David Park Meininger

Margrit Schwarz

Kevin Lustig

Masahiro Nitta

Jonathan B Houze

Steven L McKnight

Leping Li

Sharon McKendry

Marc Labelle

Yang Li

Thomas Charles Boone

Tom Boone

Patrick A Baeuerle

M Catherine Amaral

Holger Beckmann

Joyce Chi Yee Chan

R Marc Learned

Joshua Gergely

Yi Xia

Jian Zhang

Liusheng Zhu

Jackie Zeqi Sheng

Jiwen Liu

Wen-Chen Yeh

YuMei Xiong

Serena T Cutler

Helen H Hobbs

Fabienne Charles De La Brousse

Hirohiko Hasegawa

Robert P Barnes

Qiong Cao

Fabienne C De La Brousse

Arthur Y Okamoto

Chadwick Terrence King

Yumei Xiong

Margit Schwarz

Margrit Schwartz

Methods of treating metabolic diseases and disorders using a GDF15 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)

Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

Monoclonal antibodies to proprotein convertase subtilisin kexin type 9 (PCSK9)

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)

Methods of using antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)

The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, coronary heart disease, thrombosis, and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.

Modified lecithin-cholesterol acyltransferase enzymes

The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.

Methods for treating atherosclerosis

The present invention provides nucleic acids encoding a novel ABC family cholesterol transporter, SSG. The herein-disclosed sequences can be used for any of a number of purposes, including for the diagnosis and treatment of cholesterol-associated disorders, including sitosterolemia, and for the identification of molecules that associate with and/or modulate the activity of SSG.

Screening methods using sitosterolemia susceptibility gene (SSG) polypeptides

Sitosterolemia susceptibility gene (SSG): compositions and methods of use

The present invention provides compounds, pharmaceutical compositions and methods that are useful in modulating the farnesoid X receptor (FXR). As FXR is involved in negatively controlling the expression level of cholesterol 7&#x3b1;-hydroxylase (cyp7a), the rate-limiting enzyme involved in the oxidative metabolism of cholesterol into bile acids, the compounds described herein find utility in treating diseases associated with abnormally high or low cholesterol levels. In certain aspects, the FXR modulators (e.g., antagonists) described herein block the negative feed-back downregulation of cyp7a expression produced by certain cholic acids, the endogenous ligands for FXR. Moreover, as FXR forms heterodimers with the retinoid X receptor (RXR) in some cell types, modulation of the level of FXR activity in cells has a wide range of effects on a variety of biological processes which are mediated by RXR or other RXR-interacting proteins such as PPAR&#x3b3; and PPAR&#x3b1;. Thus, compounds described herein are useful in treating other biological activities such as obesity, diabetes, lipid associated disorders, cancer, inflammatory disorders, disorders involving a disrupted or dysfunctional epidermal barrier, and various other metabolic disorders.

FXR modulators

Growing community of inventors

Redwood City, CA, United States of America

Bei Shan